Définitivement à lire cette semaine pour tous les cliniciens impliqués dans le traitement des troubles liés à l'usage des opioïdes ! Nouveau guideline : Lien PDF : https://t.co/vFIdCLqZ0p @CMAJ
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @enfermeria: Management of opioid use disorders: a national clinical practice guideline By @CMAJ MARCH 5, 2018 https://t.co/aXaXf5LCJR…
RT @enfermeria: Management of opioid use disorders: a national clinical practice guideline By @CMAJ MARCH 5, 2018 https://t.co/aXaXf5LCJR…
“stepped and integrated approach” for treatment of opioid use disorders. https://t.co/TpOmm2Zsv3 #opioidcrisis #integratedcare
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @adfoxMD: Canadian guidelines for management of Opioid Use Disorder. Interesting differences from US: endorse slow-release oral morphine…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
+1000 https://t.co/DfGIFicnez
RT @hakique: If you treat opioid use disorder, here's the world's best guideline on how you should. If you don't, start. https://t.co/kmb7…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @hakique: If you treat opioid use disorder, here's the world's best guideline on how you should. If you don't, start. https://t.co/kmb7…
RT @hakique: If you treat opioid use disorder, here's the world's best guideline on how you should. If you don't, start. https://t.co/kmb7…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @adfoxMD: Canadian guidelines for management of Opioid Use Disorder. Interesting differences from US: endorse slow-release oral morphine…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
Canadian guidelines for management of Opioid Use Disorder. Interesting differences from US: endorse slow-release oral morphine & include full spectrum of harm reduction services - including supervised consumption services. https://t.co/kBrJkoecr9 https
If you treat opioid use disorder, here's the world's best guideline on how you should. If you don't, start. https://t.co/kmb7XHidWg via @CMAJ @CRISMCan
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
Love the new Canadian guidelines on treating opiate use disorder - easy-to-use - now if we can just expand access! #primarycare #publichealth https://t.co/8FvYCNkl4R
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @picardonhealth: New clinical practice guideline on management of #opioids use disorders. https://t.co/Wu1QFXsiJC via @CMAJ https://t.co…
RT @picardonhealth: New clinical practice guideline on management of #opioids use disorders. https://t.co/Wu1QFXsiJC via @CMAJ https://t.co…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
Strong push for MAT, specifically suboxone and versions thereof. https://t.co/zPSrt9MdeD
RT @picardonhealth: New clinical practice guideline on management of #opioids use disorders. https://t.co/Wu1QFXsiJC via @CMAJ https://t.co…
New clinical practice guideline on management of #opioids use disorders. https://t.co/Wu1QFXsiJC via @CMAJ https://t.co/uvFVTgRzur
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
Well of course #opioidusedisorder should be treated with prescribed medication when possible. Good to see new guidelines from #Canada published moments ago. https://t.co/VzmP7FbhoO https://t.co/xCReYIEouV
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
Some days I just want to go back, get retrained as a GP, and only do this (then I remember I'm not actually clever enough to be a GP). https://t.co/3KeEhDpdOO
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
Sera cosa de hacer mas estudios con morfina en lugar de metadona. Es tan absurdo usar metadona existiendo liberaciones prolongadas de morfina... https://t.co/EvJvUnL5iT
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
@PEMammen @TJUHospital @theEDpharmacist @JeffIMchiefs Here’s the link to the full statement. Many recs with strong evidence. https://t.co/y0RhQBml06
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @enfermeria: Management of opioid use disorders: a national clinical practice guideline By @CMAJ MARCH 5, 2018 https://t.co/aXaXf5LCJR…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @enfermeria: Management of opioid use disorders: a national clinical practice guideline By @CMAJ MARCH 5, 2018 https://t.co/aXaXf5LCJR…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
CMAJ Clinical practice guideline on management of opioid use disorders https://t.co/hFTDd9r8Ug
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: Front and centre: "Initiate opioid agonist treatment (with buprenorphine–naloxone whenever feasible), to reduce the ris…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…
RT @DavidJuurlink: This is big. New clinical practice guideline on management of opioid use disorders. https://t.co/DcES6D7E09 open-access…